Cellosaurus cell line Mel IL/R (CVCL

Cross-references
Cell line name	Mel IL/R
Accession	CVCL_B6KF
Resource Identification Initiative	To cite this cell line use: Mel IL/R (RRID:CVCL_B6KF)
Comments	Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032). Derived from site: Metastatic; Chest, hypodermis; UBERON=UBERON_0001443+UBERON_0002072.
Sequence variations	Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=30551515).
Disease	Melanoma (NCIt: C3224)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_B6KD (Mel Il)
Category	Cancer cell line
Publications	PubMed=30551515; DOI=10.1016/j.biopha.2018.11.109 Ryabaya O., Prokofieva A., Akasov R., Khochenkov D., Emelyanova M., Burov S., Markvicheva E., Inshakov A.N., Stepanova E.V. Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells. Biomed. Pharmacother. 109:2548-2560(2019)
Cell line databases/resources	cancercelllines; CVCL_B6KF
Encyclopedic resources	Wikidata; Q112129274
Entry history
Entry creation	17-Mar-2022
Last entry update	19-Dec-2024
Version number	6